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ABSTRACT
Background and the purpose of the study: Parenteral Vitamin D3 is commonly prescribed in 
some developing countries like Iran and data about its effects on serum 25(OH)D concentration 
are scanty. Current study was designed to evaluate the effects of different doses of parenteral 
vitamin D3 on serum 25(OH)D concentration.
Methods: Forty two healthy volunteer were selected and randomly assigned into 3groups. 
Groups I and II received 300000 and 600000 units of intramuscular vitamin D3and group III 
received placebo. Serum 25 (OH)D concentration were evaluated before,2 weeks, 2 months and 
4 months after injection.
Results and major conclusion: Serum 25(OH)D in groups I and II were significantly higher than 
those before injection ( <0.001). At the end of the study, serum 25(OH)D concentration in groups 
I,II, and III were 48.20 ± 28.32 ng/ml , 65.46 ± 33.52 ng/ml, and 14.38±11.14 ng/ml , respectively. 
Relative frequency of serum 25 (OH) D above 80 ng/l in groups I, II and was %20 and %33.3 
respectively. One case in group I and one case in group II (in two sessions) showed 25(OH)D 
concentration above 100 ng/ml. Vitamin D injection especially at doses higher than 300000 IU may 
be associated with 25(OH)D concentration higher than the accepted normal values.
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INTRODUCTION
In recent years numerous studies have revealed 
high prevalence of vitamin D deficiency in 
developing countries and its prevalence in Iran 
is estimated about %44 - %79 in different studies 
(1,2).
Assay of the serum 25(OH)D in Iran is limited to 
research in a few clinical laboratories in major cities 
and is not available as a routine diagnostic test. 
Therefore in most cases, parenteral vitamin D3 is 
prescribed solely based on clinical suspiciousness 
and/or serum concentration of calcium, phosphate 
and alkaline phosphates. Vitamin D deficiency can 
causes wide spectrum of clinical presentations from 
musculoskeletal pain to severe bone deformity 
(3-5), which are neither sensitive nor specific for 
diagnosis of vitamin D deficiency. As a result, blind 
administration of high doses of parenteral vitamin D 
in short interval which is a common practice in Iran 
is blindly and there are limited data on its therapeutic 
and toxic effects.
Previous studies have shown delayed and long 
duration response of serum 25(OH)D concentration 
by intramuscular injection of vitamin D3 (6-8)and it 
has been reported that   response to oral vitamin D 
products is more predictable (9).
Most studies have not compared different doses 
of parenteral vitamin D and the Present study was 
designed to evaluate the magnitude and duration of 
different parenteral doses of vitamin D3 on serum 
25(OH)D concentration.
MATERIALS AND METHODS
Study’s population and classification 
This study was conducted during winter of 2006 as 
a double-blind clinical trial in Qazvin city located 
in north-east of Iran at latitude 50 degree. Healthy 
subjects of 20-60 years old from healthy staff 
working in Booali hospital (internal medicine center 
of Qazvin) and their relatives were enrolled in the 
study. Volunteers were fully informed about the 
study protocol before the study and written consent 
was obtained. The study protocol was approved 
by the Ethics Committee of University of Medical 
Science of Qazvin. Participants using drugs containing 
vitamin D products, calcium, anticonvulsants, estrogen 
and diuretics and those who had used parenteral 
vitamin D products during last 6 months were 
excluded. Basal serum 25(OH) D concentration was 
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measured and those with serum 25(OH) D above 75 
ng/ml were excluded (10).
Volunteers were randomly assigned to 3 groups and 
were subjected to injection of  vitamin D3 in the 
first half of December 2006. Group I participants 
received 300,000 IU vitamin D3 in one side 
gluteus muscle and placebo in other side, group 
II participants received 600,000 IU vitamin D3 
(300,000 IU in each gluteus muscle) and group 3 
received placebo in each gluteus. Volunteers and 
laboratory staff were blind about assignment.
Laboratory measurement 
Five ml of blood was drawn in no fasting status 
before injections, 2 weeks, 2 months and 4 months after 
injections and samples were taken immediately to the 
laboratory, centrifuged within 30 minute of collection 
and saved below - 20 °C. After completing the study 
all serum samples were analyzed for 25 (OH) D 
concentrations. Serum 25 (OH) D concentrations was 
measured by RIA (radioimmunassay) method using 
DRG Kits. Normal range of 25(OH) D was 10- 75 
ng/ml. Intraassay and interassay coefficient of variation 
were reported %7.9 and %8.2, respectively.
Statistical analyses 
Serum 25(OH) D concentration before injection, 2 
weeks, 2 months, and 4 months after injection was 
represented as mean ± SD in each group and session. 
Serum 25(OH) D concentration of post injection 
samples were compared with pre-injection ones using 
repeated analysis of variance (ANOVA). Significance 
was considered at the level of  p < 0.05.
Relative frequency of hypervitaminosis D was 
calculated in groups I- III in each session separately 
using 2 cutoff for definition of hypervitaminosis 
D: 25(OH) D > 80 ng/ml and 25(OH) D >100 ng/
ml. SPSS 13 statistical software package was used for 
analysis.
RESULTS 
Results are from 33 participants. Nine volunteers 
dropped out from the study which for each group 
is shown in table 1 separately. There were no 
significant differences in baseline characteristics 
of participants including age, gender, and BMI 
(Table 1). Baseline serum 25 (OH) D concentration 
of participants dropped from the study showed no 
significant differences with those who completed 
the study (Table 1). Overall %61 of participants had 
vitamin D deficiency (25(OH)D ≤20 ng/ml) (10). 
Mean serum 25(OH) D concentration 2 weeks after 
vitamin D3 injection didn’t show any significant 
difference with the pre-injection serum 25(OH) D 
concentration in each group.
Mean serum 25(OH) D concentration 2 and 4months 
after injection increased significantly in groups I and 
II compared with pre-injection concentration. At 
the end of the study (4 months after injection) mean 
25(OH) D in groups I II and III were 48.20±28.32 
ng/ml, 65.46±33.52 ng/ml and 14.38+-11.14 ng/ml 
respectively (Table 2) .
At the end of the study serum 25 (OH) D continued 
rising in groups I and II (Figure 1). Groups I and 
II showed a mean increase of 23.8 and 45.15 ng/ml 
while the placebo group showed a mean decrease of 
1.38 ng/ml compared with baseline concentration.
Distribution of serum 25(OH) D concentrations is 
shown in figure 2. Cases with 25(OH) D above 80 
ng/ml (200 nmol/l ) was detected as early as 2 weeks 
after injection and also in later phases. Highest 
relative frequency of high 25(OH) D concentration 
in group I was about %20 ( at 2nd month of the 
study)and in group II was %33.3 (at the 4th 
month of the study). At the end of the study one 
case in group I and 1 case in group II (in two 
sessions) developed 25(OH) above 100 ng/ml 
(250 nmol/l). pre-injection serum 25(OH) D 
concentration in cases which developed 25(OH) D 
above 80ng/ml had no significant difference with 
cases with lower serum 25(OH)  D. Indeed, %30 of 
cases who developed high 25(OH) D had vitamin 
D deficiency before injection.
DISCUSSION
Results of the present study indicates late and 
long lasting effects of intramuscular vitamin D3. 
Two weeks after IM injection serum 25(OH) D 
concentration was not significantly different from 
pre-injection concentration.
Few studies have been designed to evaluate 
the effects of parenteral vitamin D on serum 
25(OH)D concentration. Whyte et al studied 
the effects of 80 μg/kg and 200 μg/kg doses of 
parenteral vitamin D on serum 25 (OH) D on 3 
and 6 healthy people respectively. One week 
after administration serum 25(OH) D began to 
rise which continued until the end of the study (7 
weeks). On the other hand, serum 25(OH) D began 
to increase during 4- 8 hrs after oral administration 
and maximum serum concentration was achieved 
1 week after drug administration(6).
Regarding the late onset effect of parenetral 
vitamin D, this product doesn’t seem suitable for 
patients with symptomatic vitamin D deficiency. 
Regarding to high vitamin D storage in fat tissue, it 
is expected that intramuscular administration of high 
dosage of this vitamin induce long term effects on 
serum 25(OH) D concentration. In the present study 
the curve of serum 25(OH) D concentration was still 
rising 4 months after injection in groups I and II.
In another study, 600.000 IU Vitamin D 
administered and serum 25(OH) D was evaluated 
after 4 and 12 months. Serum which were 
significantly higher after  4 (114±35 nmol/L), and 
12 months (73±13 nmol/L) compared with baseline 
(32±8 nmol/L) (P < 0.001) and increased by an 
average of 128% over the 12 months (7).
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In Heikinheimo study, an annual intramuscular 
injection of ergocalciferol (150,000 IU) normalized 
low serum 25(OH) D concentration in elderly 
people for 1 year (8). Stephens and colleagues 
treated a group of vitamin- D- depleted Asians with 
oral or intramuscular 100000 IU ergocalciferol. 
Treatment produced a sustained rise in the 
serum concentration of 25- hydroxyvitamin D, 
which lasted for 6 months. The response was more 
predictable after oral compared with intramuscular 
administration (9).
In this study mean serum 25(OH) D increased at 
maximal drug effect (4th month) at 300,000 IU, 
and 600,000 IU doses about 23.80±19.9 ng/ml (CI 
9.54-38.05) and 45.15±27.10 ng/ml (CI 28.77-
61.53), compared with pre-injection concentration 
respectively. On the other hand, mean serum 
25(OH) D of placebo group was less than baseline 
(-1.38±6.96 ng/ml) at 4th month of  the study. Mean 
increase of serum 25 (OH) D in group who received 
600000 IU was about 2 times greater than those of 
300000 IU group.
Definition of hypervitaminois D is somehow vague 
and different cutoff points of serum 25 (OH) D has 
been set for its definition, however all instances of 
vitamin D toxicity have been associated with serum 
25(OH) D concentration higher than 80 ng/ml or 
200 nmol/l (11). Therefore most of the researchers 
set the cutoff point of hypervitaminosis D serum 
level 25(OH) D at least 200 nmol/l (11,12). Using 
the cutoff point of 200 nmol/l, relative frequency 
of hypervitaminosis D in this study was about 20 
and 33%, in group I and II respectively. The most 
notable point is occurrence of the highest frequency 
of hypervitaminosis D at 4th month of study in group 
II. This study ended at 4 month, so it is entirely 
Variables Group I Group II Group III
Male, number 3 5 2
female, number 11 9 12
Total, number 14 14 14
Drop out,number 2 1 6
BMI  (Kg/m2), mean (SD) 25.0(3.6) 23.8(4.1) 24.6(4.8)
Age  (years), mean (SD) 38.7(10.2) 33.8(9.4) 33.0(11.2)
Serum 25 (OH) D at beginning the study (ng/ml), 
mean(SD)  27.24(21.30) 25.20(17.09) 25.10(14.4)
Serum 25(OH)D completed the study (ng/ml), 
mean(SD)  24.40(18.39) 20.31(13.07) 15.72(10.43)
Table 1. Basal characteristics of volunteers in 3 groups of the study
BMI-body mass index
Group I :300.000 unit vitamin D3, Group II :600.000 unit vitamin D3, Group III: placebo
Table 2. Changes of serum 25(OH)D in each session
Groups Baseline 2 weeks 8 weeks 16 weeks p
Group  I, mean (SD) 
(ng/ml) 24.4018.39 39.01(28.75) 46.25(21.16) 48.20(28.32) P<0.001*
Group II, mean(SD)
(ng/ml) 20.31±13.07 27.33±27.86 45.42V28.14 65.46±33.52 P<0.001*
Group III, mean(SD)
(ng/ml) 15.72±10.43 10.14±2.54 9.75±5.94 14.38±11.14 NS
Serum 25 (OH) D concentrations at 8 and 16 weeks after injection were significantly higher than baseline concentration in groups I and 
II. Concentration at 2 weeks did not show any significant difference with baseline level in any group.
Figure 1. Changes of vitamin D concentration in different time that were assessed after 
injection. 
Figure 1. Changes of vitamin D concentration in different time 
that were assessed after injection.
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possible that high frequency of 25(OH) D concentration  > 
200 nmol/l continue in latter months.
CONCLUSION
According to the results of this study parenteral 
administration of 300000 or 600000 units of vitamin 
D3 can be associated with 25(OH) D concentration 
that exceed the upper limits of normal and may 
causes hypervitaminosis D.
In Iran, vitamin D is commonly prescribed as 
intramuscular injection and in most cases it is 
prescr ibed without 25(OH) D concentration 
assessment and before vitamin D deficiency 
confirmation. Regarding high frequency of 
serum 25(OH) D above 200 nmol/l after parenteral 
administration, prescription of this product could be 
harmful even in vitamin D deficient subjects (in this 
REFERENCES
Hosseinpanah, F.,  Rambod, M.,  Hossein- Nejad, A.,  Larijani, B.,  Azizi, F., Association between vitamin 1.    
D and bone mineral density in Iranian postmenopausal women , Journal of Bone and Mineral Metabolism, 
2008; 26 : 86-92.
Hashemipour, S., Larijani, B., Adibi, H., 2.    Javadi, E., Sedaghat, M., Pajouhi, M., Soltani, A., Shafaei, A.R., 
Hamidi, Z., Fard, A.R., Hossein-Nezhad, A., Booya, F. Vitamin D deficiency and causative factors in the 
population of Tehran.BMC Public Health, 2004, 4:38.
Tofighi, P.,  Hossein-Nezhad, A., Sedighi, N.,  Maghbooli, Z.H.,  Larijani, B., Vertebral geometry 3.    
parameters can predict fractures, Iranian Journal of Public Health, 2007;  Suppl: 14-23.  
Hafezi, R., Hossein-nezhad, A.,  Mirsafa, M.,  Maghbooli, Z., Saghafi, H.,  Karimi, F., Larijani, 4.    
B.,Association between Vitamin D Deficiency and Unexplained Musculoskeletal Pain, Iranian Journal of 
Public Health, 2008;  Suppl.  49-54.
Maghbooli, Z., Hossein-Nezhad, A., Shafaei, A.R.,Karimi, F., Madani, F.S., Larijani, B., Vitamin D status in 5.    
mothers and their newborns in Iran, BMC Pregnancy Childbirth, 2007; 12;7:1.
Whyte, M.P., Haddad, J.G., Walters, D.D., Stamp, T.C. Vitamin D bioavailability: serum 25 hydroxy 6.    
vitamin D levels in man after oral, subcutaneous, intramuscular, and intravenous vitamin D administration. 
JCEM ,1979; 48: 906-911
Diamond, T.H., Ho, K.W., Rohl, P.G., Meerkin, M. Annual intramuscular injection of a megadose of 7.    
cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Med J Aust, 2005; 183: 10-12.
Heikinheimo, R.J., Haavisto, M.V., Harju, E.J., 8.    Inkovaara, J.A., Kaarela, R.H., Kolho, L.A., Rajala, S.A. 
Serum vitamin D level after an annual intramuscular injection of ergocalciferol. Calcif Tissue int,1991; 
49: S87.
Stephens, W.P., Klimiuk, P.S., Berry, J.L., Mawer, E.B. Annual high-dose vitamin D prophylaxis in Asian 9.    
immigrants. Lancet, 1981; 2:1199-1202
Lips, P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone 10.  
loss and fractures and therapeutic implications. Endocrine Rev 2001; 22:477-501.
Vieth, 11.  R., Chan, P.C., MacFarlane, G.D. Efficacy and safety of vitamin D intake exceeding the lowest 
observed adverse effect level. Am J Clin Nutr 2001; 73:288–94.
Vieth, R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am J Clin 12.  
Nutr ,1999; 69:842–856.
 
study %30 of cases who developed hypervitaminosis 
D were vitamin D deficient before injection).
However in most countries parenteral vitamin D 
are not used and maximum drug dosage is 50,000 IU 
per each oral product which is used for treatment of 
vitamin D deficiency.
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Figure 2. Relative frequency of hypervitaminosis D in groups I to III in different sessions of the study. Dashed lines represent two 
different cut offs for definition of hypervitaminosis D. A:group I , B: group II , C: group III 
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